New drug targets tumors from inside: early trial begins

NCT ID NCT07454642

First seen Mar 07, 2026 · Last updated Jun 09, 2026 · Updated 11 times

Summary

This early-phase trial tests a new drug called AVA6103 in about 174 adults with advanced solid tumors (like pancreatic, lung, or breast cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, aiming to kill cancer cells while limiting side effects. The main goals are to check safety and find the best dose, with initial signs of tumor shrinkage also being measured.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NEXT Oncology

    RECRUITING

    Irving, Texas, 75039, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • NEXT Oncology Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.